These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38224989)

  • 1. Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study.
    Stamp LK; Keating P; Frampton C; Barclay ML; Fanning N; Millier M; Hessian PA; O'Donnell JL
    J Rheumatol; 2024 Mar; 51(3):242-249. PubMed ID: 38224989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting.
    Maid PJ; Xavier R; Real RM; Pedersen R; Shen Q; Marshall L; Solano G; Borlenghi CE; Hidalgo RP
    J Clin Rheumatol; 2018 Jun; 24(4):177-182. PubMed ID: 29232322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia.
    Deakin CT; De Stavola BL; Littlejohn G; Griffiths H; Ciciriello S; Youssef P; Mathers D; Bird P; Smith T; O'Sullivan C; Freeman T; Segelov D; Hoffman D; Seaman SR;
    JAMA Netw Open; 2023 Jun; 6(6):e2320851. PubMed ID: 37382956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab drug and antidrug antibody levels do not predict flare risk after stopping adalimumab in RA patients with low disease activity.
    Lamers-Karnebeek FBG; Jacobs JWG; Radstake TRDJ; van Riel PLCM; Jansen TL
    Rheumatology (Oxford); 2019 Mar; 58(3):427-431. PubMed ID: 30383251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.
    Bartelds GM; Krieckaert CL; Nurmohamed MT; van Schouwenburg PA; Lems WF; Twisk JW; Dijkmans BA; Aarden L; Wolbink GJ
    JAMA; 2011 Apr; 305(14):1460-8. PubMed ID: 21486979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational study.
    Hirata S; Saito K; Kubo S; Fukuyo S; Mizuno Y; Iwata S; Nawata M; Sawamukai N; Nakano K; Yamaoka K; Tanaka Y
    Arthritis Res Ther; 2013 Sep; 15(5):R135. PubMed ID: 24286472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
    Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
    PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.
    Vogelzang EH; Kneepkens EL; Nurmohamed MT; van Kuijk AW; Rispens T; Wolbink G; Krieckaert CL
    Ann Rheum Dis; 2014 Dec; 73(12):2178-82. PubMed ID: 25115447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Biologic Drugs in Patients With Rheumatoid Arthritis and Antidrug Antibodies.
    Bitoun S; Hässler S; Ternant D; Szely N; Gleizes A; Richez C; Soubrier M; Avouac J; Brocq O; Sellam J; de Vries N; Huizinga TWJ; Jury EC; Manson JJ; Mauri C; Matucci A; Hacein Bey Abina S; Mulleman D; Pallardy M; Broët P; Mariette X;
    JAMA Netw Open; 2023 Jul; 6(7):e2323098. PubMed ID: 37436748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis.
    Finzel S; Kraus S; Figueiredo CP; Regensburger A; Kocijan R; Rech J; Schett G
    Ann Rheum Dis; 2019 Sep; 78(9):1186-1191. PubMed ID: 31142474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.
    Ulijn E; den Broeder N; Wientjes M; van Herwaarden N; Meek I; Tweehuysen L; van der Maas A; van den Bemt BJ; den Broeder AA
    Ann Rheum Dis; 2020 Jul; 79(7):867-873. PubMed ID: 32317314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Percentage of Signal Regulatory Protein α/β
    Magill L; Adriani M; Berthou V; Chen K; Gleizes A; Hacein-Bey-Abina S; Hincelin-Mery A; Mariette X; Pallardy M; Spindeldreher S; Szely N; Isenberg DA; Manson JJ; Jury EC; Mauri C
    Front Immunol; 2018; 9():2865. PubMed ID: 30568660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Analysis of the Biological Disease-modifying Antirheumatic Drug-free Condition of Adalimumab-treated Rheumatoid Arthritis Patients.
    Ito S; Kobayashi D; Hasegawa E; Takai C; Nemoto T; Lee H; Abe A; Otani H; Ishikawa H; Murasawa A; Narita I; Nakazono K
    Intern Med; 2019 Feb; 58(4):511-519. PubMed ID: 30210123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
    Quistrebert J; Hässler S; Bachelet D; Mbogning C; Musters A; Tak PP; Wijbrandts CA; Herenius M; Bergstra SA; Akdemir G; Johannesson M; Combe B; Fautrel B; Chollet-Martin S; Gleizes A; Donnellan N; Deisenhammer F; Davidson J; Hincelin-Mery A; Dönnes P; Fogdell-Hahn A; De Vries N; Huizinga T; Abugessaisa I; Saevarsdottir S; Hacein-Bey-Abina S; Pallardy M; Broët P; Mariette X;
    Semin Arthritis Rheum; 2019 Jun; 48(6):967-975. PubMed ID: 30420245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidrug antibodies against TNF-blocking agents: correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins.
    Benucci M; Li Gobbi F; Meacci F; Manfredi M; Infantino M; Severino M; Testi S; Sarzi-Puttini P; Ricci C; Atzeni F
    Biologics; 2015; 9():7-12. PubMed ID: 25733803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.
    Jani M; Chinoy H; Warren RB; Griffiths CE; Plant D; Fu B; Morgan AW; Wilson AG; Isaacs JD; Hyrich K; Barton A;
    Arthritis Rheumatol; 2015 May; 67(8):2011-9. PubMed ID: 26109489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periodontal and serum protein profiles in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitor adalimumab.
    Kobayashi T; Yokoyama T; Ito S; Kobayashi D; Yamagata A; Okada M; Oofusa K; Narita I; Murasawa A; Nakazono K; Yoshie H
    J Periodontol; 2014 Nov; 85(11):1480-8. PubMed ID: 24857321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time lag between the initiation of adalimumab after methotrexate correlates with the efficacy of adalimumab in rheumatoid arthritis patients.
    Kimura N; Suzuki K; Takeuchi T
    Mod Rheumatol; 2016 Sep; 26(5):676-80. PubMed ID: 26708943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.
    Chen DY; Chen YM; Tsai WC; Tseng JC; Chen YH; Hsieh CW; Hung WT; Lan JL
    Ann Rheum Dis; 2015 Mar; 74(3):e16. PubMed ID: 24442879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study.
    Hoxha A; Calligaro A; Tonello M; Ramonda R; Carletto A; Paolazzi G; Bortolotti R; Del Ross T; Grava C; Boaretto M; Favaro M; Teghil V; Ruffatti A; Punzi L
    Joint Bone Spine; 2016 Mar; 83(2):167-71. PubMed ID: 26750762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.